Company intelligence / Profile preview

Novel Microdevices

Baltimore, Maryland, United States

Ownership: Private
Employees: ~15
Development stage: Other

Overview

The Novel Dx system is a rapid, portable, point-of-care PCR platform delivering lab-quality results for multiple infectious diseases in under 15 minutes. It is not yet commercially available; supportive grants and NIH RADx funding confirm achievement of key technical milestones.

Therapeutic areas: Infectious Diseases
Modalities: DeviceMolecular diagnosticNucleic acid amplification test
Industry: Molecular Diagnostics

Partnerships

National Institutes of Health (NIH) RADx Tech ProgramMaryland Department of Commerce

Beyond the preview

Go deeper on Novel Microdevices.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novel Microdevices.

Explore the full profile